IMVT

Immunovant, Inc.

September 23, 2026 · pre-market

Rarity

3.33

Peak move

−14.16%

Float cap

$3.0B

Immunovant is a clinical-stage immunology company developing IMVT-1402 (imeroprubart), an anti-FcRn antibody for autoimmune diseases driven by pathogenic IgG antibodies. It is evaluating the candidate in patients with conditions such as Graves' disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, rheumatoid arthritis, Sjögren's disease, and cutaneous lupus erythematosus.

• executive_remarkSep 22

  Roivant CEO Matt Gline said at the BofA Global Healthcare Conference that Immunovant's IMVT-1402 showed ~70% ACR20, ~50% ACR50 and ~35% ACR70 in open-label D2T RA, with CLE and D2T RA updates in H2 2026 and Graves' disease/MG registration data in 2027.

  Webseekingalpha.comWebau.investing.comWebau.investing.comWebinvesting.com
• peer_disclosureSep 21 · 04:27 ET

  AstraZeneca's Alexion unit received a positive CHMP opinion from the EMA for Klygefa (gefurulimab), a subcutaneous C5 inhibitor for generalized myasthenia gravis, setting up EU approval and adding a competitor to FcRn blockers like VYVGART and Rystiggo.

  Webpharmaphorum.com
• analyst_ratingSep 21

  Piper Sandler maintained a Buy rating on Immunovant (IMVT) with a $66 price target on September 21, 2026.

  Webstockanalysis.com